pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
NOVARTIS · news · pharmadog
← back to NOVARTIS
News mentioning NOVARTIS
367
stories
8d
Roche talks up Phase 3 success rate as it unveils pipeline cuts
endpoints
10d
Lycia aims for $228M IPO to generate data on food allergy rival to Xolair
fiercebiotech
10d
Alnylam bulls and bears fight it out after business-shaking guidance cut
biospace
10d
Epkinly data only one of Genmab's make-or-break readouts ahead of steep sales erosion
biospace
10d
Pfizer makes ‘business decision’ to end phase 2 trial of autoimmune drug as program’s future uncertain
fiercebiotech
11d
Novartis ends mid-stage Fabhalta study in lupus, insists no efficacy or safety issues
biospace
14d
Hospitals’ next lucrative bet — longevity clinics
stat
14d
Novartis scraps Fabhalta study in lupus nephritis
endpoints
14d
Estuary sails into kidney disease space with $103M for gene therapies
biospace
14d
Biogen-backed Estuary nabs $93M for kidney disease gene therapy
biopharma dive
15d
AstraZeneca bulks up MASH, cardio work in up to $1.5B AI partnership with insitro
biospace
15d
Webinar: The China question: Can US biotechs lead as investment heads east?
biospace
15d
Vanda freezes Novartis-originated social anxiety program after late-stage disappointment
biospace
15d
Estuary flows out of stealth with $103M to propel kidney disease gene therapies into clinic
fiercebiotech
15d
Vanda pauses social anxiety program after ex-Novartis asset flunks phase 3 study
fiercebiotech
16d
Zealand pens up to $1.2B deal with Generate for AI-designed obesity, metabolic drugs
biospace
16d
Zealand inks $1.2B Generate pact to add multispecific proteins to obesity pipeline
fiercebiotech
17d
Novartis quietly returns a key antibiotic to US market
endpoints
17d
Merck KGaA spinout iOnctura touts PI3K delta inhibitor in metastatic eye cancer
fiercebiotech
18d
BMS’ $4.1B RayzeBio bet delivers Phase 3 radiopharma win
biospace
18d
BMS doubles up with pivotal wins in lung disease, solid tumor that offer hope for post-patent cliff growth
fiercebiotech
21d
Curium prices generic radioligand at 5% discount to Novartis' Lutathera
endpoints
21d
How Abogen went from COVID hype to a $7.8B Novartis deal
biospace
21d
GSK drinks in Chai Discovery’s AI models after wet-lab validation
fiercebiotech
21d
‘We’re making a lot of progress’: How Nobel-winning optogenetics is being harnessed by biotechs
fiercebiotech
22d
NIH funding uncertainty thwarts U.S. researchers
stat
22d
Argenx falls as Sjögren’s setback offsets celiac drug progress
biopharma dive
22d
Ono pays Biohaven $80M for protein degrader; UK pulls Valneva's chikungunya shot
endpoints
22d
Argenx shutters Sjogren's study, losing blockbuster expansion opportunity for Vyvgart
biospace
22d
Big Pharma–backed Matchpoint scores $150M series B, advancing autoimmune asset
biospace
← prev
page 2 of 13
next →
